Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MI078 Phase 1 in Healthy Subjects
NCT06982651Phase 1Completed
- Sponsor
- Nanjing Minova Pharmaceutical
- Start
- Sep 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MI078 in postpartum depression (PPD), sponsored by Nanjing Minova Pharmaceutical. Primary endpoints: Incidence, severity, and causality of Adverse Events (AEs) and Serious Adverse Events (SAEs), Vital signs and 4 more. Started Sep 2023; status: completed.
02
Drugs
MI078
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on NCT06982651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06982651.